PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Pulmatrix, Inc. Exhibit
EX-99.1 2 d786089dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   August 5,…
To view the full exhibit click here

About PULMATRIX, INC. (NASDAQ:PULM)

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.